Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant
Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy
in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer
and an Oncotype Recurrence…

Principal Investigator: Levine, Ellis G

A bilingual virtually-based intervention (PEDALL) for the prevention of weight gain in childhood ALL patients considering key genetic and sociodemographic risk factors

Principal Investigator: Kelly, Kara M

A Phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy for advanced non-small cell lung cancer

Principal Investigator: Jain, Prantesh

A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Principal Investigator: Wang, Eunice S

An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T…

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

GI-200: A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in
Advanced Refractory Gastric Cancer Patients

Principal Investigator: Mukherjee, Sarbajit

(S1931) Phase III Trial of Immunotherapy-Based Drug Combination Therapy With Or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE TRIAL)

Principal Investigator: George, Saby

A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors

Principal Investigator: Puzanov, Igor

A Phase 0 Study of EGF-depleting therapy CIMAvax-EGF in Combination with Standard Therapy for RAS- and BRAF wild-type Metastatic Colorectal Cancer

Principal Investigator: Vadehra, Deepak

A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

Principal Investigator: Frederick, Peter

2215-CL-0203 A Phase 1/2, Multicenter, Open-Label, Randomized, Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for…

Principal Investigator: Wang, Eunice S

Phase 2 study of iberdomide maintenance therapy following autologous stem cell transplant in patients with multiple myeloma

Principal Investigator: Hillengass, Jens

(ANHL1931) A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

Principal Investigator: Twist, Clare J

(AHOD2131) A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Principal Investigator: Kelly, Kara M

(FT576-101) A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Principal Investigator: McCarthy, Philip L

A012103: OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY

Principal Investigator: Levine, Ellis G

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta T Cells in Adults with B Cell Malignancies

Principal Investigator: Cortese, Matthew J

(ARST2032) A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

Principal Investigator: Gupta, Ajay

EA2176 A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients

Principal Investigator: Mukherjee, Sarbajit

A Phase 1 Study of ASCIMINIB in combination with dasatinib, prednisone, and blinatumomab in patients with BCR-ABL1 positive (BCR-ABL1+) B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML)

Principal Investigator: Wang, Eunice S

S2107 Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Principal Investigator: Vadehra, Deepak

Money Matters 101: A Pilot Community-Based Financial Health Educational Program

Principal Investigator: Bouchard, Elizabeth G

A PHASE 1, OPEN-LABEL, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF NC525 IN SUBJECTS WITH ADVANCED MYELOID NEOPLASMS

Principal Investigator: Griffiths, Elizabeth A

A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination with
Endocrine Therapy in Patients Age 70 and Older with Hormone Receptor Positive
Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition

Principal Investigator: Levine, Ellis G

A022104:THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II/III TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY REGARDING CLINICAL COMPLETE RESPONSE AND DISEASE-FREE SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

Principal Investigator: Vadehra, Deepak